In the mice bearing B16 melanoma, co-administration of PBAE-CDN and anti-PD-1 antibody markedly slowed tumor growth compared with anti-PD-1 plus unencapsulated CDN or anti-PD-1 monotherapy [88]. This evidence concerns the gene NT5C and melanoma.